You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
健康元(600380.SH):妥布黴素吸入溶液今年的醫保談判是公司的重點工作
格隆匯 07-27 08:44

格隆匯7月27日丨健康元(600380.SH)近期在接待機構投資者調研時表示,妥布黴素吸入溶液目前在各省份掛網、入院等工作正常推進中,已在全國20多個省份完成掛網,同時公司也已經打通線上銷售渠道,京東藥房可以直接購買。因獲批的時間未能趕上2022年的醫保談判,今年的銷售還是依靠公司自主開發,妥布黴素吸入溶液今年的醫保談判也是公司的重點工作,公司正在積極準備相關工作。

支氣管擴張症在國內患者約2,000萬人,40歲以上人羣患病率約為1.2%。妥布黴素吸入溶液的成功上市,將可改變肺部伴肺部銅綠假單胞菌感染的支氣管擴張患者霧化吸入治療領域在國內外均無藥可用的現狀。製劑的銷售情況易受到國內醫藥行業政策變動、市場環境變化等因素影響,未來的銷售情況尚存在不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account